{"id":"W2943108118","doi":"10.1093/annonc/mdz127","title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":488,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Cilag; National Center for Advancing Translational Sciences; National Cancer Institute; Foundation Medicine; Ipsen; EMD Serono; Sanofi; Fidia Farmaceutici; Eisai; Astellas Pharma; Merck Sharp and Dohme; Genentech; GlaxoSmithKline; UroGen Pharma; Pfizer; Incyte; Exelixis; Kidney Cancer Association; Merck; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Amgen","keywords":"Medicine; Docetaxel; Urothelial cancer; Paclitaxel; Pembrolizumab; Oncology; Internal medicine; Cancer; Chemotherapy; Randomized controlled trial; Bladder cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009126515,0.000253388,0.002710537,0.0003329496,0.00001175067,0.000001638136,0.0002098975,0.0002445354,0.0003924284],"category_scores_gemma":[0.001117848,0.0002035596,0.0004793855,0.0003866458,0.0003313766,0.00008801796,0.00006324868,0.0002040535,0.000004959696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009749288,"about_ca_system_score_gemma":0.001327079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001309488,"about_ca_topic_score_gemma":0.0003591557,"domain_scores_codex":[0.9966806,0.0003732154,0.001749213,0.0003776862,0.0004587008,0.0003606536],"domain_scores_gemma":[0.9966195,0.001049497,0.00124209,0.0005161678,0.0004492701,0.0001235013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9103345,0.002598484,0.00004440982,0.0002184637,0.0007177831,0.00002406379,0.0009663253,0.00002785824,0.008117405,0.0001107314,0.0006399567,0.07620005],"study_design_scores_gemma":[0.9180848,0.04180964,0.0001868891,0.0003874239,0.0004362988,0.000003482334,0.0001278052,0.00003450113,0.0306149,0.00009449785,0.008080275,0.0001394873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877571,0.001540226,0.000005579401,0.0007250923,0.001627723,0.002843498,0.0005644446,0.00001246792,0.004923911],"genre_scores_gemma":[0.9942096,0.004413344,0.0001790502,0.000101353,0.000139165,0.0001516778,0.00005211673,0.00002949214,0.0007242188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07606056,"threshold_uncertainty_score":0.8300921,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08149898714952458,"score_gpt":0.4267595225361745,"score_spread":0.3452605353866499,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}